18.1: Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.

Mechanism of Action of Beta-Lactam Antibiotics

Beta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered beta-lactam ring that structurally mimics the D-alanyl-D-alanine dipeptide—the natural substrate for the enzyme transpeptidase, also known as a penicillin-binding protein (PBP). By irreversibly binding to the active site of this enzyme, beta-lactams prevent the cross-linking of peptide chains within the peptidoglycan. This disruption halts cell wall assembly and activates murein hydrolases—enzymes that break down peptidoglycan—ultimately leading to bacterial cell lysis.

Beta-lactams are classified into four main groups: penicillins, cephalosporins, monobactams, and carbapenems. Penicillins (e.g., penicillin G, ampicillin) were the first beta-lactams developed and are primarily used to treat Gram-positive infections, though many have expanded Gram-negative coverage. Cephalosporins (e.g., cefazolin, ceftriaxone) offer broader-spectrum activity and improved resistance to beta-lactamase enzymes produced by the bacteria. Monobactams (e.g., aztreonam) are active mainly against Gram-negative bacteria and are especially useful in patients with penicillin allergies. Carbapenems (e.g., meropenem, imipenem) have the broadest spectrum of all beta-lactams and are typically reserved for severe or multidrug-resistant infections.

Due to their structural diversity and broad clinical utility, beta-lactams remain among the most extensively used and well-studied classes of antibiotics in modern medicine.

Mechanism of Action of Glycopeptide Antibiotics

Glycopeptide antibiotics, such as vancomycin, teicoplanin, and dalbavancin, act through a mechanism distinct from that of beta-lactams. These agents bind directly to D-alanyl-D-alanine termini of peptidoglycan precursors, forming stable complexes that prevent enzymatic access to the substrate. This binding sterically blocks the activity of transglycosylase, the enzyme responsible for catalyzing glycan strand elongation, and transpeptidase, which mediates peptide cross-linking. As a result, both polymerization and cross-linking steps in cell wall biosynthesis are arrested.

Unlike beta-lactams, glycopeptides do not inhibit these enzymes directly; instead, they act by shielding the target site. This indirect mechanism is particularly advantageous against bacteria that have acquired beta-lactam resistance through the production of beta-lactamases or the alteration of penicillin-binding proteins (PBPs). Glycopeptides are most effective against Gram-positive organisms because their large molecular size and hydrophilicity prevent them from penetrating the outer membrane of Gram-negative bacteria.